Skip to main content
. Author manuscript; available in PMC: 2008 Feb 20.
Published in final edited form as: Cancer Immunol Immunother. 1994 Aug;39(2):73–83. doi: 10.1007/BF01525312

Fig. 3.

Fig. 3

Lysis of the IFNγ-treated Ewing's sarcoma cell lines 6647, TC-71, and RD-ES by TIL 1143 is inhibited by the mAb W6/32 and anti-CD3, but not anti-Thy1.2. mAb failed to block lymphokine-activated killer cell lysis of these targets in the same experiment (data not shown), but did inhibit TIL lysis of the HLA-A2+ melanomas 501-mel and 624-mel